Momentum is building in various markets, with small caps, biotech stocks, and certain individual stocks gaining ground. The gains are attributed to various factors, including lower rates, mergers and acquisitions activity, and progress in areas such as clinical trials and copper exploration. However, some outlets are also sounding notes of caution, suggesting that the momentum may be overextending in some areas, such as low-quality momentum stocks.